SCHEMBL23757550

SCHEMBL23757550

C=CCCCOc1ccc(C(=O)OC)c(N)c1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
KDM4E B2RXH2 5/20 0.49
GAA P10253 4/20 0.49
HSD17B10 Q99714 3/20 0.49
MAPT P10636 3/20 0.49
HPGD P15428 2/20 0.49
GLA P06280 2/20 0.49
CASP1 P29466 1/20 0.49
CASP7 P55210 1/20 0.49
ATM Q13315 1/20 0.49
ABL1 P00519 1/20 0.48
CFTR P13569 2/20 0.45
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
MAOB P27338 3/20 0.40
MAOA P21397 2/20 0.40
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23757924 0.93 ALDH1A1 (0.50) ALDH1A1L3MBTL1KDM4EGAAHSD17B10
SCHEMBL23757486 0.90 ALDH1A1 (0.50) ALDH1A1L3MBTL1KDM4EGAAHSD17B10
SCHEMBL23757235 0.86 ALDH1A1 (0.48) ALDH1A1L3MBTL1KDM4EHSD17B10HPGD
SCHEMBL4251894 0.85 ALDH1A1 (0.55) ALDH1A1L3MBTL1KDM4EGAAHSD17B10
SCHEMBL23758029 0.83 ALDH1A1 (0.51) ALDH1A1L3MBTL1KDM4EGAAHSD17B10
SCHEMBL11153695 0.82 ALDH1A1 (0.55) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL27122631 0.82 ALDH1A1 (0.55) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL10362606 0.82 ALDH1A1 (0.58) ALDH1A1KDM4EGAAHSD17B10MAPT
SCHEMBL5096583 0.80 MAOA (0.52) ALDH1A1L3MBTL1TSHRMAOBMAOA
SCHEMBL23757392 0.79 KDM4E (0.41) ALDH1A1L3MBTL1KDM4EHSD17B10HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12594277-B2 Macrocyclic ULK1/2 inhibitors SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2026-04-07 US disclosed
US-20230099804-A1 MACROCYCLIC ULK1/2 INHIBITORS Sanford Burnham Prebys Medical Discovery Institute 2023-03-30 US disclosed
CN-115515588-A Macrocyclic ULK1/2 inhibitors 萨克生物研究学院 2022-12-23 CN disclosed
EP-4103183-A1 MACROCYCLIC ULK1/2 INHIBITORS Salk Institute for Biological Studies (US) 2022-12-21 EP disclosed
WO-2021163627-A1 MACROCYCLIC ULK1/2 INHIBITORS SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 2021-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12594277-B2 Macrocyclic ULK1/2 inhibitors ULK1, ULK2, ULK3 ALDH1A1 4428/4885L3MBTL1 1720/4885KDM4E 2260/4885
US-20230099804-A1 MACROCYCLIC ULK1/2 INHIBITORS ULK1, ULK2, ULK3 ALDH1A1 4090/4885L3MBTL1 1570/4885KDM4E 2324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.